Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study

Torben Plesner; Hendrik-Tobias Arkenau; Francesca Gay; Monique C. Minnema; Mario Boccadoro; Philippe Moreau; Jamie Cavenagh; Aurore Perrot; Jacob P. Laubach; Jakub Krejcik; Tahamtan Ahmadi; Carla de Boer; Diana Chen; Christopher Chiu; Jordan M. Schecter; Paul G. Richardson

doi:10.1111/bjh.15879

Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study

Torben Plesner, Hendrik-Tobias Arkenau, Francesca Gay, Monique C. Minnema, Mario Boccadoro, Philippe Moreau, Jamie Cavenagh, Aurore Perrot, Jacob P. Laubach, Jakub Krejcik, Tahamtan Ahmadi, Carla de Boer, Diana Chen, Christopher Chiu, Jordan M. Schecter, Paul G. Richardson

Research output: Contribution to journal › Letter › Academic › peer-review

Original language	English
Pages (from-to)	E35-E39
Journal	British Journal of Haematology
Volume	186
Issue number	3
DOIs	https://doi.org/10.1111/bjh.15879
Publication status	Published - Aug 2019

Keywords

daratumumab
monoclonal antibody
multiple myeloma
relapsed/refractory multiple myeloma
plasma cell disorders

Access to Document

10.1111/bjh.15879

Cite this

Plesner, T., Arkenau, H.-T., Gay, F., Minnema, M. C., Boccadoro, M., Moreau, P., Cavenagh, J., Perrot, A., Laubach, J. P., Krejcik, J., Ahmadi, T., de Boer, C., Chen, D., Chiu, C., Schecter, J. M., & Richardson, P. G. (2019). Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study. British Journal of Haematology, 186(3), E35-E39. https://doi.org/10.1111/bjh.15879

@article{c2b0a3944b8043579ea4305537a63340,

title = "Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study",

keywords = "daratumumab, monoclonal antibody, multiple myeloma, relapsed/refractory multiple myeloma, plasma cell disorders",

author = "Torben Plesner and Hendrik-Tobias Arkenau and Francesca Gay and Minnema, {Monique C.} and Mario Boccadoro and Philippe Moreau and Jamie Cavenagh and Aurore Perrot and Laubach, {Jacob P.} and Jakub Krejcik and Tahamtan Ahmadi and {de Boer}, Carla and Diana Chen and Christopher Chiu and Schecter, {Jordan M.} and Richardson, {Paul G.}",

note = "Funding Information: All authors developed the manuscript, provided final submission approval and confirmed that the protocol was followed and that the data were accurate and complete. This study was sponsored by Janssen Research and Development. Medical writing and editorial support were provided by Kimberly Carmony, PhD, of MedErgy, and were funded by Janssen Global Services, LLC. The authors thank the patients who participated in this study and their families, as well as the study co-investigators, research nurses and coordinators at each of the clinical sites. Results of this analysis were presented, in part, at the 59th American Society of Hematology (ASH) Annual Meeting & Exposition, December 9–12, 2017, Atlanta, GA, USA. The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at https://www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at http://yoda.yale.edu.",

year = "2019",

month = aug,

doi = "10.1111/bjh.15879",

language = "English",

volume = "186",

pages = "E35--E39",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "3",

}

Plesner, T, Arkenau, H-T, Gay, F, Minnema, MC, Boccadoro, M, Moreau, P, Cavenagh, J, Perrot, A, Laubach, JP, Krejcik, J, Ahmadi, T, de Boer, C, Chen, D, Chiu, C, Schecter, JM & Richardson, PG 2019, 'Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study', British Journal of Haematology, vol. 186, no. 3, pp. E35-E39. https://doi.org/10.1111/bjh.15879

Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study. / Plesner, Torben; Arkenau, Hendrik-Tobias; Gay, Francesca et al.
In: British Journal of Haematology, Vol. 186, No. 3, 08.2019, p. E35-E39.

Research output: Contribution to journal › Letter › Academic › peer-review

TY - JOUR

T1 - Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study

AU - Plesner, Torben

AU - Arkenau, Hendrik-Tobias

AU - Gay, Francesca

AU - Minnema, Monique C.

AU - Boccadoro, Mario

AU - Moreau, Philippe

AU - Cavenagh, Jamie

AU - Perrot, Aurore

AU - Laubach, Jacob P.

AU - Krejcik, Jakub

AU - Ahmadi, Tahamtan

AU - de Boer, Carla

AU - Chen, Diana

AU - Chiu, Christopher

AU - Schecter, Jordan M.

AU - Richardson, Paul G.

N1 - Funding Information: All authors developed the manuscript, provided final submission approval and confirmed that the protocol was followed and that the data were accurate and complete. This study was sponsored by Janssen Research and Development. Medical writing and editorial support were provided by Kimberly Carmony, PhD, of MedErgy, and were funded by Janssen Global Services, LLC. The authors thank the patients who participated in this study and their families, as well as the study co-investigators, research nurses and coordinators at each of the clinical sites. Results of this analysis were presented, in part, at the 59th American Society of Hematology (ASH) Annual Meeting & Exposition, December 9–12, 2017, Atlanta, GA, USA. The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at https://www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at http://yoda.yale.edu.

PY - 2019/8

Y1 - 2019/8

KW - daratumumab

KW - monoclonal antibody

KW - multiple myeloma

KW - relapsed/refractory multiple myeloma

KW - plasma cell disorders

UR - http://www.scopus.com/inward/record.url?scp=85063618819&partnerID=8YFLogxK

U2 - 10.1111/bjh.15879

DO - 10.1111/bjh.15879

M3 - Letter

C2 - 30931524

SN - 0007-1048

VL - 186

SP - E35-E39

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 3

ER -

Plesner T, Arkenau HT, Gay F, Minnema MC, Boccadoro M, Moreau P et al. Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study. British Journal of Haematology. 2019 Aug;186(3):E35-E39. doi: 10.1111/bjh.15879

Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study

Keywords

Access to Document

Other files and links

Cite this